Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 12 74 58 29 6 43 15 71

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:987
ICD9CM 34 704.0
MeSH 43 D000505
NCIt 49 C50575
SNOMED-CT 67 56317004
ICD10 32 L65.9
UMLS via Orphanet 72 C0002170
Orphanet 58 ORPHA79364
UMLS 71 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and alopecia-intellectual disability syndrome, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is SASH1 (SAM And SH3 Domain Containing 1). The drugs Acitretin and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include Hair, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1066)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 35.1 HR FOXN1 AIRE
2 alopecia-intellectual disability syndrome 34.6 LSS AHSG
3 alopecia-mental retardation syndrome 34.4 MBTPS2 LSS AHSG
4 atrichia with papular lesions 32.9 VDR HR ANTXR1
5 nail disorder, nonsyndromic congenital, 1 32.7 TP63 MBTPS2 AIRE
6 hypotrichosis 32.6 MBTPS2 LSS HR GJA1 DCAF17
7 hypotrichosis 11 32.3 RIN2 RBM28 DCAF17
8 telogen effluvium 31.7 VDR HR
9 keratosis 31.6 MBTPS2 GJA1 DSP
10 skin disease 31.3 VDR TP63 KRT14 GJA1 DSP
11 palmoplantar keratosis 30.9 SASH1 MBTPS2 GJA1 DSP
12 ectodermal dysplasia 30.9 TP63 KRT14 GJA1 DSP AIRE
13 familial woolly hair syndrome 30.7 MBTPS2 GJA1 DSP
14 pachyonychia congenita 1 30.6 MBTPS2 KRT14 DSP
15 hair disease 30.5 VDR MBTPS2 LSS KRT14 FOXN1 DSP
16 angular cheilitis 30.1 MBTPS2 AIRE
17 cardiomyopathy, dilated, with woolly hair and keratoderma 29.8 GJA1 DSP
18 alopecia areata 12.9
19 palmoplantar keratoderma and congenital alopecia 2 12.7
20 alopecia, androgenetic, 1 12.7
21 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 12.7
22 androgenic alopecia 12.7
23 palmoplantar keratoderma and congenital alopecia 1 12.7
24 frontal fibrosing alopecia 12.6
25 alopecia totalis 12.6
26 mandibulofacial dysostosis with alopecia 12.6
27 alopecia, neurologic defects, and endocrinopathy syndrome 12.6
28 central centrifugal cicatricial alopecia 12.6
29 alopecia-mental retardation syndrome 1 12.5
30 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 12.5
31 polyposis, skin pigmentation, alopecia, and fingernail changes 12.5
32 diffuse alopecia areata 12.5
33 alopecia-mental retardation syndrome 2 12.5
34 alopecia-contractures-dwarfism-intellectual disability syndrome 12.4
35 alopecia-contractures-dwarfism mental retardation syndrome 12.4
36 alopecia-mental retardation syndrome 4 12.4
37 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.4
38 alopecia areata 1 12.4
39 alopecia, congenital 12.4
40 cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma 12.4
41 alopecia-epilepsy-oligophrenia syndrome of moynahan 12.3
42 odonto onycho dysplasia with alopecia 12.3
43 ichthyosis alopecia eclabion ectropion mental retardation 12.3
44 hypergonadotropic hypogonadism and partial alopecia 12.2
45 alopecia areata 2 12.2
46 alopecia, androgenetic, 2 12.2
47 alopecia intellectual disability syndrome 2 12.2
48 alopecia-mental retardation syndrome 3 12.2
49 alopecia universalis onychodystrophy vitiligo 12.2
50 woodhouse-sakati syndrome 12.2

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.65 GJA1 SASH1
2 Decreased viability GR00249-S 9.65 LSS TP63
3 Decreased viability GR00381-A-1 9.65 LSS
4 Decreased viability GR00386-A-1 9.65 FOXN1 LSS VDR
5 Decreased viability GR00402-S-2 9.65 DSP EDNRA
6 Increased CFP-tsO45G cell surface transport GR00360-A-1 8.62 ANTXR1 GJA1

MGI Mouse Phenotypes related to Alopecia:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ANTXR1 AR AUTS2 DSP EDNRA FOXN1
2 cellular MP:0005384 10.34 ANTXR1 AR AUTS2 DCAF17 DSP EDNRA
3 growth/size/body region MP:0005378 10.34 AHSG AIRE ANTXR1 AR AUTS2 DSP
4 endocrine/exocrine gland MP:0005379 10.25 AIRE ANTXR1 AR AUTS2 EDNRA FOXN1
5 mortality/aging MP:0010768 10.21 AIRE ANTXR1 AR AUTS2 DSP EDNRA
6 craniofacial MP:0005382 10.2 ANTXR1 AR DSP EDNRA GJA1 HR
7 embryo MP:0005380 10.18 AR AUTS2 DSP EDNRA FOXN1 GJA1
8 immune system MP:0005387 10.17 AIRE ANTXR1 AR EDNRA FOXN1 GJA1
9 hematopoietic system MP:0005397 10.16 AIRE AR EDNRA FOXN1 GJA1 HR
10 digestive/alimentary MP:0005381 10.14 AIRE AR DSP EDNRA HR KRT14
11 integument MP:0010771 10.1 AR DSP EDNRA FOXN1 GJA1 HR
12 hearing/vestibular/ear MP:0005377 10.02 AHSG EDNRA FOXN1 GJA1 HR KRT14
13 muscle MP:0005369 9.92 AHSG AR DSP EDNRA FOXN1 GJA1
14 neoplasm MP:0002006 9.86 AIRE ANTXR1 AR AUTS2 FOXN1 HR
15 reproductive system MP:0005389 9.85 AIRE ANTXR1 AR DCAF17 FOXN1 GJA1
16 skeleton MP:0005390 9.65 AHSG ANTXR1 AR AUTS2 EDNRA FOXN1
17 vision/eye MP:0005391 9.23 AIRE EDNRA FOXN1 GJA1 HR KRT14

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
4
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8 Orange Approved Phase 4
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Drospirenone Approved Phase 4 67392-87-4 68873
14
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
15
Phylloquinone Approved, Investigational Phase 4 84-80-0
16 fluindione Approved, Investigational Phase 4 957-56-2
17
Warfarin Approved Phase 4 81-81-2 6691 54678486
18
Dalteparin Approved Phase 4 9005-49-6
19
Phenindione Approved, Investigational Phase 4 83-12-5 4760
20
Rivaroxaban Approved Phase 4 366789-02-8
21
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
22
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
23
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
24
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
25
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
26
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
29
Gemcitabine Approved Phase 4 95058-81-4 60750
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
32
Histamine Approved, Investigational Phase 4 51-45-6 774
33
Cetirizine Approved Phase 4 83881-51-0 2678
34
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
35
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
36
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
37
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
38
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
39 Menaquinone Investigational Phase 4 1182-68-9
40 Keratolytic Agents Phase 4
41 Vitamins Phase 4
42 Antiprotozoal Agents Phase 4
43 Antimalarials Phase 4
44
protease inhibitors Phase 4
45 HIV Protease Inhibitors Phase 4
46 Anti-Infective Agents, Local Phase 4
47 Neuroprotective Agents Phase 4
48 Methylprednisolone Acetate Phase 4
49 Insulin, Globin Zinc Phase 4
50 insulin Phase 4

Interventional clinical trials:

(show top 50) (show all 473)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Unknown status NCT03473600 Phase 4 Triamcinolone acetonide injection
4 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
5 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
6 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
7 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
8 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
9 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
10 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
12 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
13 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
14 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
15 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
16 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
17 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
18 Modified SALT Score for Assessment of Alopecia Areata Recruiting NCT04412148 Phase 4 Triamcinolone Acetonide
19 Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study Recruiting NCT04207931 Phase 4 Topical steroid class I-II;Triamcinolone Acetonide;Doxycyline;Minoxidil
20 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
21 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
22 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
23 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
24 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
25 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
26 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
27 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
28 Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids Active, not recruiting NCT04228029 Phase 4 Intralesional Steroid Injection
29 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Active, not recruiting NCT03800979 Phase 4 Tofacitinib
30 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
31 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
32 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
33 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
34 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
35 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
36 CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Unknown status NCT00054184 Phase 3 docetaxel;paclitaxel poliglumex
37 TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
38 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
39 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
40 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
41 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
42 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
43 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
44 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
45 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
46 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
47 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
48 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
49 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
50 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 29

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

40
Breast, Skin, Lung, T Cells, Ovary, Thyroid, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 16817)
# Title Authors PMID Year
1
Study on the chemical constituents of nut oil from Prunus mira Koehne and the mechanism of promoting hair growth. 61
32283192 2020
2
A comprehensive review of biochemical factors in herbs and their constituent compounds in experimental studies on alopecia. 61
32360043 2020
3
LncRNA-XIST promotes dermal papilla induced hair follicle regeneration by targeting miR-424 to activate hedgehog signaling. 61
32243962 2020
4
The influence of interferon on healthy and diseased skin. 61
30527631 2020
5
LC-MS bioanalytical method for simultaneous determination of latanoprost and minoxidil in the skin. 61
32473548 2020
6
Herbal preparations for the treatment of hair loss. 61
31680216 2020
7
Isolated DHEAS production by an adrenal neoplasm: Clinical, biochemical and pathologic characteristics. 61
32195126 2020
8
Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. 61
32202088 2020
9
Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? 61
32333494 2020
10
Accelerated hair growth by combining thread monofilament and minoxidil in female androgenetic alopecia. 61
31789457 2020
11
The effect of nitrogen plasma on the skin and hair follicles: a possible promising future for the treatment of alopecia. 61
31811380 2020
12
Gomez-López-Hernández syndrome: A case report with clinical and molecular evaluation and literature review. 61
32302043 2020
13
Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging. 61
32289732 2020
14
Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. 61
32406107 2020
15
Pantothenic acid promotes dermal papilla cell proliferation in hair follicles of American minks via inhibitor of DNA Binding 3/Notch signaling pathway. 61
32304761 2020
16
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. 61
32394350 2020
17
Identification and verification of EOMEs regulated network in Alopecia areata. 61
32353685 2020
18
The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. 61
32165196 2020
19
Nevus psiloliparus: Newly described histopathological features from transverse sections. 61
32034785 2020
20
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. 61
32571540 2020
21
Evaluation of quality of life of patients with hirsutism among Turkish women: A single-center cross-sectional study. 61
32564506 2020
22
Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic: What it whispers to us? 61
32530503 2020
23
Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. 61
32529393 2020
24
Is a de novo nonsense variant in the ASPDH gene the cause of ulcerative skin lesions in a Holstein calf? 61
31908106 2020
25
Syphilis: A Contemporary Clinicopathologic Assessment. 61
32568824 2020
26
Multicentric B-cell lymphoma with presumed paraneoplastic generalized cutaneous sclerosis in a dog. 61
31930629 2020
27
Adalimumab-induced scalp psoriasis with severe alopecia as a paradoxical effect in a patient with Crohn's disease; successfully treated with ustekinumab. 61
32510744 2020
28
Trichoscopic Findings Of Discoid Lupus Erythematosus Alopecia: A Cross-Sectional Study. 61
32502590 2020
29
Correction to: Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study. 61
32350810 2020
30
Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. 61
32412314 2020
31
Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study. 61
32277388 2020
32
Platelet-Rich Plasma and its Use for Cicatricial and Non-Cicatricial Alopecias: A Narrative Review. 61
32557337 2020
33
Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use. 61
32469180 2020
34
Erosive pustular dermatosis of the scalp: a multicentre study. 61
31954062 2020
35
Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. 61
32516434 2020
36
Erosive pustular dermatosis of the scalp: causes and treatments. 61
32516510 2020
37
The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia. 61
32378360 2020
38
Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects. 61
31039644 2020
39
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report. 61
32500595 2020
40
Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. 61
32052367 2020
41
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis. 61
32478968 2020
42
Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia. 61
31529675 2020
43
Cross Sectional Quality of Life Assessment in Patients with Androgenetic Alopecia. 61
32520416 2020
44
Study of serum vitamin D levels in men with premature androgenetic alopecia. 61
32516435 2020
45
Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. 61
32538225 2020
46
The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. 61
32166351 2020
47
Cyclosporin A-loaded poly(d,l-lactide) nanoparticles: a promising tool for treating alopecia. 61
32552553 2020
48
Elevated serum tumour necrosis factor-like weak inducer of apoptosis in alopecia areata: a possible marker of disease severity. 61
31587331 2020
49
Clinical, Dermoscopic and In-Vivo Reflectance Confocal Microscopy Evaluation of a Case of Graham Little-Piccardi-Lassueur Syndrome Successfully Treated with Narrowband-UVB Phototherapy. 61
32533553 2020
50
Sequential Scalp Assessment in Hair Regeneration Therapy Using an Adipose-Derived Stem Cell-Conditioned Medium. 61
31490301 2020

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SASH1 NM_015278.5(SASH1):c.1849G>A (p.Glu617Lys)SNV Pathogenic/Likely pathogenic 156162 rs587781245 6:148855021-148855021 6:148533885-148533885
2 EMILIN2 , LPIN2 , METTL4 , MYL12A , MYL12B , MYOM1 , NDC80 , SMCHD1 , TGIF1 GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168)copy number loss Uncertain significance 523239 18:1345040-3479168

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.62 GJA1 DSP

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinocyte differentiation GO:0030216 9.33 TP63 FOXN1 DSP
2 epidermis development GO:0008544 9.26 TP63 KRT14 FOXN1 DSP
3 thymus epithelium morphogenesis GO:0097536 8.62 FOXN1 AIRE

Molecular functions related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.02 VDR TP63 HR AR AIRE

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....